XCeed Bioreactor from Honeywell's UOP to Remove Contaminants


UOP LLC, a wholly-owned subsidiary of Honeywell International Inc (HON), recently announced the commercial launch of its XCeed bioreactor system – a highly efficient wastewater treatment system. The integrated advanced bioreactor technology is expected to remove all types of contaminants from industrial waste water streams using a high-performing biological process.

Globally, norms and regulations for wastewater treatment standards have been getting stricter with increasing focus on environmental issues. The new bioreactor system will help manufacturers and industries meet these stringent policies in a reliable and cost-effective manner.  

Leveraging on the XCeed bioreactor system technology, which features a simple mechanical design, modular installation system and low energy consumption, the integrated treatment process is expected to gain widespread acceptability across industries.

The system has been launched commercially after having been successfully implemented in over 50 locations, including food and beverage, chemical and textile manufacturing, groundwater remediation, and refinery and petrochemical applications.

The new integrated bioreactor system further enhances Honeywell's position as a global leader in the field of process development and contaminant removal solutions.

Honeywell is a global diversified technology and manufacturing company with a wide range of aerospace products and services, control, sensing and security technologies for buildings, homes and industry. It also produces turbochargers, automotive products, specialty chemicals, electronic and advanced materials, process technology for refining and petrochemicals, and energy efficient products and solutions for homes, business and transportation.

Honeywell currently has a Zacks Rank #3 (Hold). Other stocks that look promising in the industry include Federal Signal Corp. (FSS), ITT Corporation (ITT) and Macquarie Infrastructure Company LLC (MIC), each with a Zacks Rank #2 (Buy).

Read the Full Research Report on ITT
Read the Full Research Report on HON
Read the Full Research Report on FSS
Read the Full Research Report on MIC

Zacks Investment Research

View Comments (0)